Evaluation of the Comparative Efficacy of Etoricoxib and Ibuprofen for Treatment of Patients With Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial

Cardiovascular and Gastrointestinal Effects of Etoricoxib in the Treatment of Osteoarthritis: A Systematic Review and Network Meta-analysis

“…During 12 weeks of treatment, the risk of GI events was comparable to that found with other comparators (OR=0.38, 95% CrI=0.03∼4.28, P=0.21 compared with placebo, OR=0.94, 95% CrI=0.04∼20.35, P=0.49 with celecoxib and OR=0.49, 95% CrI=0.03∼7.21, P=0.29 with ibuprofen), while the risk of GI events was significantly lower than that found with naproxen (OR=0.18, 95% CrI=0.03∼1.17, P=0.03) ( Figure 4A). Among studies that included patients with OA of the lower extremities and involved treatment of 12 weeks, etoricoxib showed significantly lower risk of GI events compared with naproxen (OR=0.18, 95% CrI=0.01∼2.73, P=0.06), while there was no significant difference compared with placebo, celecoxib, and ibuprofen (OR=0.24, 95% CrI=0.01∼ 6.07, P=0.18 with placebo, OR=0.99, 95% CrI=0.01∼ 162.70, P=0.50 with celecoxib, OR=0.33, 95% CrI=0.00∼ 20.83, P=0.27 with ibuprofen) ( Figure 4B) [26][27][28][29][30]. In analysis according to dose of etoricoxib, 30 mg of etoricoxib showed comparable risk of GI events with celecoxib, ibuprofen and placebo during 12 weeks.…”

“…A final 10 studies were included in our study after further reviewing full texts [21][22][23][24][25][26][27][28][29][30]: eight were excluded because they were not RCTs, three were without peer review, seven involved non-OA patients, one did not involve etoricoxib, 16 reported no outcome of interest, two did not utilize adequate comparators, and one was excluded for other reasons (Figure 1). …”

“…The results were consistent when we included studies of patients with OA of the hip or knee joints over a duration of 12 weeks (OR=0.65, 95% CrI=0.08∼4.91, P=0.33 with placebo, OR=0.99, 95% CrI=0.01∼95.15, P=0.50 with celecoxib, OR=0.84, 95% CrI=0.07∼10.07, P=0.44 with ibuprofen, OR=2.11, 95% CrI=0.14∼31.37, P=0.72 with naproxen) ( Figure 3B) [26][27][28][29][30]. In analysis according to dose of etoricoxib, 30 mg of and 60 mg or higher dose of etoricoxib did not increase the risk of CV events compared with comparators during 12 weeks ( Figure 3C).…”

NSAR und Coxibe: aktueller Stand

“…Den günstigen, therapeutisch erwünschten, Wirkungen stehen zahlreiche Nebenwirkungen entgegen, die gerade bei älteren Menschen mit Komorbiditäten zu schweren Komplikationen führen können. Das erhebliche Risiko schwerer, mitunter lebensbedrohlicher, gastrointestinaler Komplikationen hat zur gezielten Entwicklung der Cox-2-Inhibitoren (Coxibe) geführt, für die in Doppelblindstudien eine Reduktion der Häufigkeit gastrointestinaler Komplikationen gezeigt werden konnte [2,5,31,32,36,42]. …”

Conventional and Novel Pharmaceutical Dosage Forms on Prevention of Gastric Ulcers

“…Two other COX-2 selective NSAIDs, etoricoxib (Arcoxia®) and lumircoxib (Prexige®), received European approval for use in rheumatoid arthritis, osteoarthritis, and acute gout or osteoarthritis, respectively. COX-2-selective NSAIDs demonstrate comparable analgesia and anti-inflammatory effects to nonselective NSAIDs in patients with rheumatoid arthritis and osteoarthritis (36)(37)(38)(39)(40). At their defined therapeutic doses, COX-2-selective NSAIDs show at least a 200-to 300-fold selectivity for inhibition of COX-2 over COX-1 (36).…”